Last reviewed · How we verify
cisplatin + vinorelbine
Cisplatin and vinorelbine work together as a chemotherapy combination to kill cancer cells by damaging DNA and disrupting microtubule formation.
Cisplatin and vinorelbine work together as a chemotherapy combination to kill cancer cells by damaging DNA and disrupting microtubule formation. Used for Non-small cell lung cancer, Ovarian cancer, Breast cancer.
At a glance
| Generic name | cisplatin + vinorelbine |
|---|---|
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Drug class | Chemotherapy combination (platinum agent + vinca alkaloid) |
| Target | DNA (cisplatin); tubulin/microtubules (vinorelbine) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cisplatin is a platinum-based alkylating agent that cross-links DNA strands, preventing replication and transcription. Vinorelbine is a semi-synthetic vinca alkaloid that binds to tubulin and disrupts microtubule dynamics, halting cell division. Together, they provide synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Non-small cell lung cancer
- Ovarian cancer
- Breast cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Peripheral neuropathy
- Nephrotoxicity
- Ototoxicity
- Alopecia
Key clinical trials
- Study of Bendamustine, Gemcitabine and Vinorelbine Regimen in Relapsed/Refractory Classical Hodgkin Lymphoma (PHASE3)
- Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer (PHASE3)
- Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma (PHASE3)
- Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] (PHASE3)
- A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer (PHASE3)
- Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC (PHASE1)
- A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features (PHASE3)
- Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cisplatin + vinorelbine CI brief — competitive landscape report
- cisplatin + vinorelbine updates RSS · CI watch RSS
- Merck KGaA, Darmstadt, Germany portfolio CI